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L E T T E R TO TH E ED I TOR
Screening procedure for SARS‐CoV‐2 infection combining
triage, nasopharyngeal swab and serological test in allogeneic
stem cell transplantation recipients undergoing outpatient
posttransplant follow‐up
To the Editor,
In Italy, the first severe acute respiratory syndrome coronavirus
2 (SARS‐CoV‐2) positive patient was identified on February 21,
2020 and as of June 30, 2020 more than 240,000 people have
been diagnosed and over 34,000 have died.1 In our country, the
overall incidence of symptomatic SARS‐CoV‐2 infection, called
coronavirus disease 2019 (COVID‐19), is 396 cases every 1000
inhabitants. Our hematologic center is located in the northern‐
east of Italy, where this data decrease to 269 out of 1000 in-
habitants (http://covid19.intelworks.io/). However, despite the
availability of data on prevalence of symptomatic SARS‐CoV‐2
infection (COVID‐19) in the general population the data on real
number of asymptomatic SARS‐CoV‐2 carriers are unavailable.1‐4
When the first patient with COVID‐19 was diagnosed in our
Hospital, we were faced with the dilemma of how to counteract,
in everyday clinical practice, the spread of symptomatic and
asymptomatic SARS‐CoV‐2 infection in our allogeneic‐stem cell
transplant (Allo‐SCT) recipients undergoing post‐SCT outpatient
monitoring at our day hospital ward (DH).4
To reduce the risk of infection spread and to minimize clinical
staff exposure, Allo‐SCT patients admitted to our DH strictly fol-
lowed the prevention practices as recommended and published by
the European group for blood and marrow transplantation (EBMT),
including hygiene procedures, surgical mask and social distancing.5
Unless necessary, caregivers were not admitted to the DH.5,6 Before
entering the DH, all Allo‐SCT patients have been specifically
screened in a waiting area by health care workers (using personal
proctective equipment) with a triage procedure, which consisted of a
questionnaire including four items to assess patients' clinical status:
presence of symptoms suggestive for SARS‐CoV‐2 infection (such as
fever >37.5°C, cough, dyspnea, headache, diarrhea, anosmia, and
ageusia), and any personal possible exposure to the SARS‐CoV‐2
virus. In addition to the triage procedure, to further improve the
SARS‐CoV‐2 infection screening in our Allo‐SCT outpatient popula-
tion, we adopted a stringent and active surveillance combining two
diagnostic tests. In detail, from April, 2020 a real‐time polymerase
chain reaction (RT‐PCR) has been performed every 7–14 days, using
nasopharyngeal swab (NPS), providing results in 4‐6 h and from May,
2020, one rapid serological test (Cellex qSARS‐CoV‐2 immunoglobilin
G (IgG)/immunoglobulin M (IgM) point‐of‐care antibodies diagnostic
rapid test) has been performed for each patient, providing results in
10min. In the same period of time all healthcare workers were ac-
tively screened with a NPS for SARS‐CoV‐2 (every 14 days) and no
positive cases were recorded.
Actually, the approximate sensitivity and specificity for NPS are
around 70% and 95%, respectively.7‐9 Moreover, Cellex qSARS‐CoV‐2
IgG/IgM rapid test is a lateral flow immunoassay intended for the
SARS‐CoV‐2 Ab qualitative detection and differentiation approved
by FDA, whose declared sensitivity and specificity are 93.75%
and 96.40%.
The aim of this combined approach was to identify, as early as
possible, not only the symptomatic SARS‐CoV‐2 cases but also
the asymptomatic SARS‐CoV‐2 carriers to avoid the spread of the
viral infection between vulnerable patients and the healthcare
workers and also to define the real prevalence of SARS‐CoV‐2
infection (including cases with or without clinical manifestations)
in our high‐risk immunocompromised outpatient population.
The consecutive patients who received this combined
screening procedure over a 2‐month period (April‐May 2020) and
the transplant related characteristics are reported in Table 1. Of
the 70 Allo‐SCT patients, 44 (63.0%) were transplanted from
an unrelated donor. Forty‐two (60%) were receiving im-
munosuppressive treatment either for prophylaxis‐12 (28.5%)
and for graft‐versus‐host disease (GVHD) treatment‐30 (71.5%)
and 6 patients were receiving active therapy for relapse of their
underling hematologic disease. We performed a total of 185 RT‐
PCR tests from NPSs, with a median of 4 RT‐PCR tests per pa-
tient (range: 2–7), and one rapid serological test for each patient.
Taking into account that the SARS‐CoV‐2 epidemic peak in Italy
was registered on March 20, 2020, for detecting the serological
response to SARS‐CoV‐2 infection after an appropriate period of
time from the potential virus exposure, we performed all the
rapid serological test in May, 2020.
Only 8% of the triage procedures were positive for fever but
none of the 70 Allo‐SCT tested patients reported other symptoms
potentially SARS‐CoV‐2 related. All the 185 RT‐PCR NPS were
negative. Only 1 out of 70 (1.5%) rapid serological test was po-
sitive (both IgG and IgM positive) in an asymptomatic patient 12
months after the unrelated Allo‐SCT for a lymphoma and re-
ceiving immunosuppressive treatment for a chronic GVHD. The
patient was immediately evaluated by an infectious disease team;
they repeated the RT‐PCR test for SARS‐CoV‐2 on NPS and ex-
tended it on gastric aspirate (tubage), and both were negative.
Moreover, a quantitative serological test (euroimmune anti‐
SARS‐CoV‐2 Elisa) was performed, resulting negative (IgG and
IgM antibodies). So that, the infectious disease team concluded
for a false positive rapid serological test.
As a conclusive result of this stringent monitoring, we found that
our Allo‐SCT tested population was SARS‐CoV‐2 free (neither
asymptomatic nor symptomatic cases).
Although we found no positive cases, we believe our
screening experience worthy of reporting for different reasons: it
represents a viable monitoring option in clinical practice in a
specific setting of patients (Allo‐SCT) at high risk of developing a
severe SARS‐CoV‐2 infection.2,5,6 Moreover, the concomitant
evaluation of the two available tests (NPS and rapid serological
test) might improve the detection of SARS‐CoV‐2 infection pre-
valence (we underline that the sensibility of NPS alone is around
70%) and it might be useful to verify the efficacy of the preven-
tion practices that have been adopted according to the EBMT
recommendations.5 Last but not least, the absence of detection
during the pandemic period (combining two different tests), of
positive SARS‐CoV‐2 cases in our Allo‐SCT population, re-
presented for our patients, for their family members and also for
the healthcare workers, a feeling of security. We would also un-
derline the complete compliance of all the 70 patients for per-
forming both the NPS and the serological test.
We are aware that, up to now, it is not completely clear which is
the sensitivity and specificity of the rapid, qualitative serological
SARS‐CoV‐2 diagnostic tests in a setting of immunocompromised
patients in which a reduction of immune response and consequently
of seroconversion is expected.10‐12 However, with this concern, our
experience suggests that a vulnerable Allo‐SCT population, if
screened with a combined approach and instructed properly, might
avoid the diffusion of SARS‐CoV‐2 infection.5
In conclusion, in Allo‐SCT an active screening for SARS‐CoV‐2
infection could be performed with a combined approach, including
triage procedure, molecular (RT‐PCR from NPS) and serological tests.
This approach could be useful to define the prevalence of SARS‐CoV‐2
infection (including symptomatic and asymptomatic cases) in the
context of a vulnerable population and it should be taken into account
as a useful tool especially in the case of a regrowth of SARS‐CoV‐2
virus spread.
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TABLE 1 Patients' and transplants related characteristics
Number of tested patients (2‐month period) 70
Gender (M/F) 36/34
Median age, years (range) 56 (23–73)
Median time from Allo transplant, months (range) 12 (2–112)
Type of donor
Matched unrelated 44 (63.0%)
Matched sibling 12 (17.0%)
Haploidentical 14 (20.0%)
Hematologic disease
Acute leukemia 46 (65.5%)
Lymphoma 13 (18.5%)
Chronic myeloproliferative disease 5 (7.0%)
Myelodysplastic syndrome 4 (6.0%)
Multiple myeloma 2 (3.0%)
Previous transplant (autologous transplant) 10 (14.0%)
Ongoing immunosuppressive therapy 42 (60.0%)
Steroid or calcineurine inhibitors alone 18 (42.5%)
Calcineurine inhibitors + steroid 17 (32.5%)
Imatinib/ruxolitinib + steroid 4 (10.0%)
Extracorporeal photoapheresis + steroids 3 (7.0%)
Ongoing salvage treatment 6 (8.5%)
Chemotherapy alone 1 (16.5%)
Decitabine + donor lymphocytes infusion (DLI) 2 (33.5%)
Gilteritinib 1 (16.5%)
DLI alone 2 (33.5%)
Graft versus host disease (GVHD) 30 (43.0%)
Acute GVHD 11 (15.5%)
Chronic GVHD 19 (27.0%)
No. patients with COVID‐19 symptoms 0
Nasopharyngeal swabs (NPS)
No. of total SARS‐CoV‐2 NPS 185
NPS/patient, median (range) 4 (2–7)
No. of positive NPS 0
Serologic tests
No. of SARS‐CoV‐2 serologic rapid test 70
No. positive SARS‐CoV‐2 serologic rapid test 1 (1.5%)
Abbreviations: COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe
acute respiratory syndrome coronavirus 2.
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